The UK Competition Authority publishes full decision on excessive pricing in the pharmaceutical sector and focuses on intention and evidence (Pfizer / Flynn)

KEYWORDS
Reference

UK Competition Authority, Pfizer/Flynn, CE/9742-13, 7 December 2016

The CMA’s decision relies heavily on evidence of the parties’ intentions in applying competition rules. On 15 June 2017, the UK Competition and Markets Authority (CMA) published the full non-confidential version of its decision to fine Pfizer and Flynn a record £84.2m for their excessive and unfair pricing of phenytoin sodium capsules (used in treating epilepsy) in the UK. The CMA’s reasoning focuses heavily on the fact that both the parties had no reasonable explanation for the price increase (for

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Burges Salmon (London)
    United Kingdom 4 contributions 2309 visits
  • Simmons & Simmons (London)
    United Kingdom 12 contributions 3996 visits

Quotation

Nathdwarawala Shachi, Ajit Kainth, The UK Competition Authority publishes full decision on excessive pricing in the pharmaceutical sector and focuses on intention and evidence (Pfizer / Flynn), 7 December 2016, e-Competitions December 2016, Art. N° 84760

Visites 445

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues